Not independent
Tenure on this board
4.3 yrs
Meeting calendar
NUTX · Annual meeting · Thursday, April 23, 2026
Nutex Health Inc
7 nominees · 3 ballot items.
Election of seven directors; advisory vote to approve executive compensation (say-on-pay); ratification of Grant Thornton LLP as independent registered public accounting firm for 2026.
Market cap
$1.1B
1Y TSR
+55.2%
Board grade
C
Record date
Feb 27, 2026
Filing
DEF 14A
Meeting concluded · Apr 23, 2026
Follow how the vote landed and what changed on Nutex Health Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORRe-election of seven director nominees (Thomas T. Vo; Warren Hosseinion; Cheryl Grenas; Frank E. Jaumot; Michael L. Reed; Scott J. Saunders; Kelvin Spears) each for one-year terms.
- 2
Advisory Vote on the Compensation of Our Named Executive Officers
ManagementBoard: FORNon-binding, advisory ('say-on-pay') vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.
- 3
Ratification of the Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Grant Thornton LLP as Nutex Health Inc.’s independent registered public accounting firm for the year ending December 31, 2026.
Director elections
Nominees on the ballot7
Not independent
Tenure on this board
4.3 yrs
Also a director at
Cardio Diagnostics Holdings Inc (CDIO)General Purpose Acquisition Corp (GPAC)Veraxa Biotech Holding AG (VRXA)
Independent
Tenure on this board
4.3 yrs
Michael L. Reed, MPH
Independent
Tenure on this board
New nominee
Not independent
Tenure on this board
2.3 yrs
Scott J. Saunders, MPPM
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
1.0 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Pertento Partners LLP | 5.4% | 373,970 | $36M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 219,131 | $21M |
| 3 | AMERICAN CENTURY COMPANIES INC | 3.0% | 203,450 | $19M |
| 4 | BlackRock, Inc. | 2.8% | 190,823 | $18M |
| 5 | Topline Capital Management, LLC | 2.6% | 177,800 | $17M |
| 6 | BlackRock, Inc. | 2.2% | 151,848 | $14M |
| 7 | STATE STREET CORP | 1.8% | 123,177 | $12M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 104,021 | $10M |
| 9 | MILLENNIUM MANAGEMENT LLC | 1.3% | 89,571 | $9M |
| 10 | UBS Group AG | 1.0% | 66,670 | $6M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Nutex Health Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Reference
Frequently asked questions
- When is the Nutex Health Inc 2026 annual meeting?
- Nutex Health Inc (NUTX) holds its 2026 annual shareholder meeting on Thursday, April 23, 2026.
- What is the record date for the Nutex Health Inc 2026 meeting?
- The record date for the Nutex Health Inc 2026 meeting is Friday, February 27, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Nutex Health Inc's 2026 meeting?
- The board is presenting 7 director nominees at the Nutex Health Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Nutex Health Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Nutex Health Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.